AS
CLRB icon

Altshuler Shaham’s Cellectar Biosciences CLRB Stock Holding History

Altshuler Shaham’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-667
Closed – – 300
2023
Q2 		$0 Hold
667
– – ﹤0.01% 334
2023
Q1 		$0 Hold
667
– – ﹤0.01% 390
2022
Q4 		$0 Buy
+667
New +$40K ﹤0.01% 478

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Altshuler Shaham's CLRB Position: Q3 2023 in Review

Altshuler Shaham sold out of Cellectar Biosciences (CLRB) in Q3 2023, closing a stake of 667 shares.

Altshuler Shaham first reported a position in CLRB in Q4 2022 and held it in 3 quarters. The position peaked at $0 in Q2 2023. 19 funds tracked by Wall St. Rank hold CLRB as of Q3 2023.

  • Altshuler Shaham reported no remaining Cellectar Biosciences position as of Q3 2023 after selling out during the quarter.
  • Altshuler Shaham sold 667 Cellectar Biosciences shares in Q3 2023.
  • Altshuler Shaham first reported a position in Cellectar Biosciences in Q4 2022 and held it in 3 quarters.
  • Altshuler Shaham's Cellectar Biosciences position peaked at $0 in Q2 2023.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2023.

Based on Altshuler Shaham's 13F filing for Q3 2023, filed 13 Nov 2023.